Pan Cancer T

Foundation date

09/09/2020

Sector

#Biotechnology - Therapeutics

Subsector

Pan Cancer T is a biotech spin-out that builds further on 20 years of pioneering in adoptive cell therapy developed in the laboratories of Erasmus MC. We intend to lead the fight against solid cancers through T cell receptor (TCR) gene engineered T-cell therapy. Especially, those solid cancers for which there are limited treatment options and a poor prognosis.

Upcoming events

Latest news

  • Mayne Pharma and Mithra announce FDA approval of HALOETTE®, a generic version of NUVARING®

    8 hours ago

  • S-Biomedic welcomes Pascal Yvon to lead its B2B commercial activities

    Tuesday August 2nd 2022

  • Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial

    Monday August 1st 2022